Lung cancer has shown a decrease in incidence and mortality in recent decades; however,
it remains one of the cancers with the highest incidence and ranks first in cancerrelated …

The identification of oncogenic driver alterations that underlie sensitivity to small inhibitors
has led to growing interest in identifying additional targetable oncogenes in nonsmall cell …

RAS (H-ras, K-ras, and N-ras), as the second largest mutated gene driver in various human
cancers, has long been a vital research target for cancer. Its function is to transform the …

Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation
and immune evasion, and is one of the most important targets for biological therapy …

Aim. To explore the clinicopathological and prognostic role of PIK3CA gene mutation and
expression in non-small-cell lung cancer (NSCLC) patients. Methods. A systematic and …

Introduction Little is known about the prevalence, prognosis, and response to treatment of
advanced NSCLC harboring multiple genomic alterations. Methods The French Biomarkers …

Abstract EGFR (exon 19 and exon 21) mutations in patients with advanced non-small cell
lung cancer (NSCLC) treated by EGFR-TKIs are associated with a better survival; while …

Abstract MicroRNA-363-3p (miR-363-3p) reportedly plays crucial roles in tumor
development and progression in many types of cancers. However, its role in papillary thyroid …

Simple Summary For many patients with advanced cancer, pleural effusion is the only
accessible specimen for establishing a pathological diagnosis. Some pleural effusion cell …

PIK 3 CA mutation represents a clinical subset of diverse carcinomas. We explored the
status of PIK 3 CA mutation and evaluated its genetic variability, treatment, and prognosis in …